Stockreport

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy [Yahoo! Finance]

Tenaya Therapeutics, Inc.  (TNYA) 
PDF Tenaya Therapeutics, Inc. Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correc [Read more]